# NodThera

> NodThera, renamed Rezera Inc. in September 2026, is a Boston-based clinical-stage biotechnology company developing oral small-molecule NLRP3 inhibitors. Lead candidate ruvonoflast reduced inflammatory biomarkers in Phase 2, with a Phase 3 peripheral artery disease trial planned for the first half of 2027; trabzanoflast is being developed for neuroinflammatory disease. These are investigational medicines, not commercially available treatments.

- **Founded:** 2016
- **Headquarters:** Boston, United States
- **Founders:** Alan P. Watt (Founder and Chief Scientific Officer)
- **Products:** Ruvonoflast (NT-0796), Trabzanoflast (NT-0150), NT-0249, NT-0167
- **Notable:** Raised a $40 million Series A in 2018 and $55 million Series B in 2020., Reported positive Phase 1 readouts for NT-0796 and NT-0249 in September 2022., Published preclinical obesity and neuroinflammation findings in 2024.

## Products & services

- **Ruvonoflast (NT-0796)** — Investigational oral, brain- and tissue-penetrant NLRP3 inhibitor. RESOLVE-1 Phase 2 met its inflammation endpoint in September 2026, with no body-weight effect; Phase 3 in peripheral artery disease is planned for H1 2027.
- **Trabzanoflast (NT-0150)** — Investigational oral NLRP3 inhibitor for neuroinflammatory disease; Phase 1 results in 55 healthy participants reported September 30, 2026 supported further clinical development.
- **NT-0249** — Historical clinical-stage NLRP3 inhibitor with Phase 1 data and preclinical obesity research. Not listed among the two programs on the current Rezera pipeline page.
- **NT-0167** — Historical lead NLRP3 inhibitor evaluated in Phase 1 by 2020; it is not the current lead program.

## Achievements

- Raised a $40 million Series A in 2018 and $55 million Series B in 2020.
- Reported positive Phase 1 readouts for NT-0796 and NT-0249 in September 2022.
- Published preclinical obesity and neuroinflammation findings in 2024.
- Published Parkinson’s disease biomarker research in Movement Disorders in 2025.
- Reported RESOLVE-1 met its primary inflammation endpoint in September 2026.
- Reported Phase 1 trabzanoflast CNS exposure and tolerability findings in September 2026.

## Latest updates

- **2026-09** — September 30: trabzanoflast Phase 1 results in 55 participants showed high CNS exposure and generally good tolerability.
- **2026-09** — September 23: announced an accepted late-breaking presentation of RESOLVE-1 at AHA Scientific Sessions, scheduled for November 7, 2026.
- **2026-09** — September 16: announced plans for the REVEAL-PAD observational study.
- **2026-09** — September 9: renamed NodThera Inc. to Rezera Inc. and announced positive RESOLVE-1 inflammation results, no body-weight effect, and planned H1 2027 Phase 3 development in PAD.

## Links

- Website: https://www.rezera.com/
- LinkedIn: https://www.linkedin.com/company/rezera/
- Twitter/X: https://twitter.com/NodThera

---

Profile page: https://yespress.io/nodthera
Published by YesPress — https://yespress.io
Last updated: 2026-10-04